Recently, publicly listed companies in Beijing E-Town have been releasing their financial reports from the first quarter of 2024.

Benefiting from a high-quality business environment, many of these companies gave seen substantial increases in both revenue and profit, with all reporting strong first-quarter results.

Beijing Oriental Electronics (BOE)'s Q1 2024 report shows an operating income of 45.89 billion yuan ($6.45 billion), a year-on-year increase of 20.84 percent, and a net profit attributable to shareholders of 984 million yuan, a year-on-year increase of 297.8 percent.

According to Omdia data, BOE has maintained the highest global shipment volume in the TV display sector for six consecutive years. 

Prices of BOE TV products are recovering. [Photo/beijingetown.com.cn]  

NAURA Technology Group Co's Q1 2024 report shows an operating income of 5.86 billion yuan, a year-on-year increase of 51.36 percent, and a net profit attributable to shareholders of 1.13 billion yuan, a year-on-year increase of 90.40 percent.

NAURA attributes its revenue growth to its continuous focus on its core business, in-depth understanding of customer needs, enhancement of technological research and development, and continuous improvement of its core competitiveness. 

Researchers at Sinocelltech conduct experiments. [Photo/beijingetown.com.cn]

Its market share in process equipment for integrated circuits, such as etching, thin film deposition, cleaning, and furnace tubes, has been steadily increasing.

SinoCellTech's Q1 2024 report shows an operating income of 613 million yuan, a year-on-year increase of 86.30 percent, and a net profit attributable to shareholders of 74.1974 million yuan, a turnaround from a loss in the same period last year.

Currently, Sinocelltech has four listed products, with several new drugs and vaccines at various stages of development. These cover a range of fields including malignant tumors, autoimmune diseases, genetic disorders, and disease prevention.